Background: Invasive lobular carcinoma (ILC) of the breast has epidemiological,
Methods:
We included all breast cancers from female patients tested at our institute between 1992 and 2016 (n = 3469) for which pathology data were available.
ILC proportion comparison according to mutational status was performed by a chisquared test. The impact of susceptibility genes on ILC proportion was investigated by univariate logistic regression with wild-type patients as reference.
Results and discussion: There were 265 (7.64%) ILC: 2/342 (0.58%) in BRCA1 patients, 24/238 (10%) in BRCA2 patients, 1/57 (1.75%) in TP53 patients and 238/ 2832 (8.4%) in non-carriers. The majority of breast cancers in all groups were invasive ductal and ductal in situ carcinomas. The difference in ILC proportion was highly significant (P < 0.001). Compared to wild-type patients, BRCA1 was associated with a lower ILC proportion (OR 0.064 [95% CI 0.016;0.259], P < 0.0001).
BRCA2 OR was 1.222 [95%CI 0.785;1.902] (P = 0.374), TP53 OR was 0.195 [95%CI 0.027;1.412] (P = 0.105). ILC are therefore underrepresented in BRCA1 and TP53 mutation carriers. Formal significance (P = 0.05) was not reached for TP53, but statistical power was only 38%. Based on ILC incidence in the general population, we make the hypothesis that BRCA1 and TP53 do not predispose to ILC, as the few occurrences of ILC in mutation carriers could be attributed to chance and not to germline mutations. Our observations will be useful to clinical cancer geneticists managing patients with ILC, as a BRCA1 or TP53 mutation in these patients would be unlikely. Genetic counseling should be adapted accordingly.
K E Y W O R D S
BRCA1, BRCA2, genetic susceptibility to disease, invasive lobular carcinoma of the breast, Li- is the only ILC-specific susceptibility gene, along with a common, low-penetrance polymorphism at the 7q34 locus. 9 In this study, we collected data on 3469 consecutive breast cancers diagnosed in female patients. We compared 637 cancers in carriers of BRCA1, BRCA2 and TP53 germline mutations with 2832 cancers in non-carriers (wild-type patients) regarding ILC frequency.
We show that ILC is underrepresented in carriers of BRCA1 and TP53 mutations. Given the rarity of ILC in these patients, we also make the hypothesis that their risk of ILC is close to, if not similar, to the general population risk. Our observations strengthen the hypothesis that even though both are invasive epithelial breast carcinomas, ILC and IDC are different diseases.
| PATIENTS AND METHODS
We included all consecutive invasive and ductal in situ breast cancers diagnosed in female patients tested at our Cancer Genetics Clinic (Gustave Roussy Cancer Institute, Villejuif, France) between 1992 and 2016, and for which pathology data were available.
Patients had been referred to us when cancer susceptibility was suspected, for example breast cancer ≤age 40, breast cancer with one relative with breast cancer ≤50, or breast cancer with a relative with ovarian cancer for BRCA1/2,classical Li-Fraumeni criteria, Chompret criteria, or breast cancer ≤age 30 for TP53. 10, 11 Informed consent was obtained, and germline DNA testing was performed using different methods depending on the period, for example SSCP, fluorescence, Sanger and NGS sequencing, qPCR and MLPA.
Statistical analyses were carried out with the SAS software (SAS Institute Inc, Cary, NC, USA). The significance level was set at 0.05. 
| DISCUSSION
In this retrospective study of nearly 3500 breast cancers, the difference in ILC proportion according to the mutational status was highly significant. ILC was significantly underrepresented in BRCA1 mutation carriers compared to wild-type patients with an OR of 0.064 (P < 0.0001). TP53 germline mutations were associated with an 80% reduction in the odds of ILC (OR = 0.195), admittedly with a P-value of 0.105, meaning we came close but did not reach significance.
That should not be a reason to dismiss our results as we only had 38% statistical power to detect a difference at the consensus 0.05 level. One hundred and twelve breast cancers in patients with TP53 mutations out of a total sample size of 6769 would have been required in order to have 80% power, but that would be hard to achieve without multicentre collaborations considering the rarity of Li-Fraumeni. Furthermore, the OR was lower than 0.3 and therefore indicate a strong relationship with ILC, suggesting a real, meaningful difference between the two groups. 12 There were no differences for
BRCA2.
Surprisingly, the issue of breast cancer type in patients with genetic susceptibility to the disease is hardly addressed in the literature, the most striking example being the large, multi-consortia study The question raised by our results is whether BRCA1 and TP53
predispose to ILC at all. Our data do not allow for definitive conclusions, but we make the hypothesis they do not. Indeed, estimates for average annual breast cancer incidence in the general population are 118/100 000. 18 For BRCA1, our patients had an average age of 51.3 at last follow-up. Combining incidence and last follow-up, 19 breast cancers would have been expected, two of them (10%) ILC.
This is exactly the observed number in our study. As for TP53, it is conceivable that one single occurrence of ILC could be due to chance, even more so considering that the only patient with ILC was diagnosed at the age of 55, while breast cancers in Li-Fraumeni are commonly seen in very young patients. 14 Our observations have direct implications for clinical cancer geneticists. Indeed, they will now be aware that a BRCA1 or TP53 mutation is unlikely in a patient with ILC. Genetic counseling should be adapted accordingly, that is no mention of a possible >40% lifetime risk of ovarian cancer as seen with BRCA1 or of a potential risk of multiple cancers regardless of age as seen in Li-Fraumeni syndrome. 19 Patients might experience reduced stress levels as a result, considering the well-documented physical and psychological consequences of ovarian and of Li-Fraumeni-associated cancers. [20] [21] [22] Compared to other cancers (IDC included), ILC shows unusually high levels of familial clustering, pointing toward a major contribution of genetic, inherited factors to the disease. 23 Only one clinically relevant ILC-specific susceptibility gene, CDH1, has been identified so far. The possibly null, at best minor, implication of BRCA1 and TP53 in ILC causality tells us there is a lot to discover regarding genetic susceptibility to ILC. We hope whole exome sequencing studies in ILC families will soon provide an answer. Our observations on the genetic specificities of ILC are all the more relevant today. Odds Ratios (OR) represent the risk of ILC in mutation carriers vs patients with no mutation.
